These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35398467)

  • 41. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae.
    Elemam A; Rahimian J; Doymaz M
    J Clin Microbiol; 2010 Oct; 48(10):3558-62. PubMed ID: 20686085
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment.
    Wang F; Zhou Q; Yang X; Bai Y; Cui J
    PLoS One; 2021; 16(10):e0258426. PubMed ID: 34648556
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the synergy of ceftazidime/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales.
    Mataraci Kara E; Yilmaz M; Istanbullu Tosun A; Özbek Çelik B
    J Chemother; 2020 Jul; 32(4):171-178. PubMed ID: 32375606
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.
    Gill CM; Aktaþ E; Alfouzan W; Bourassa L; Brink A; Burnham CD; Canton R; Carmeli Y; Falcone M; Kiffer C; Marchese A; Martinez O; Pournaras S; Satlin M; Seifert H; Thabit AK; Thomson KS; Villegas MV; Nicolau DP;
    Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2533-2541. PubMed ID: 34291323
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Inoculum Effect in the Era of Multidrug Resistance: Minor Differences in Inoculum Have Dramatic Effect on MIC Determination.
    Smith KP; Kirby JE
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784837
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.
    Sader HS; Castanheira M; Shortridge D; Mendes RE; Flamm RK
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827415
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhanced bacterial killing with a combination of sulbactam/minocycline against dual carbapenemase-producing Acinetobacter baumannii.
    Chandran S; Manokaran Y; Vijayakumar S; Shankar BA; Bakthavatchalam YD; Dwarakanathan HT; Yesudason BL; Veeraraghavan B
    Eur J Clin Microbiol Infect Dis; 2023 May; 42(5):645-651. PubMed ID: 36905566
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of polymyxin B in combination with meropenem, amikacin and gentamicin against Klebsiella pneumoniae clinical isolates co-harbouring aminoglycoside-modifying enzymes, bla
    Firmo EF; Oliveira Júnior JB; Scavuzzi AML; Alves LC; Brayner FA; Veras DL; Lopes ACS
    J Glob Antimicrob Resist; 2020 Sep; 22():511-514. PubMed ID: 32344124
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessment of the in vitro activity of ceftazidime/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015-2017).
    Rossolini GM; Stone GG
    Int J Antimicrob Agents; 2020 Sep; 56(3):106111. PubMed ID: 32721602
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synergism of eravacycline combined with other antimicrobial agents against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii.
    Li Y; Cui L; Xue F; Wang Q; Zheng B
    J Glob Antimicrob Resist; 2022 Sep; 30():56-59. PubMed ID: 35660472
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
    Emeraud C; Escaut L; Boucly A; Fortineau N; Bonnin RA; Naas T; Dortet L
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections.
    Wareham DW; Momin MHFA; Phee LM; Hornsey M; Standing JF
    J Antimicrob Chemother; 2020 Jan; 75(1):135-139. PubMed ID: 31617905
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
    Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China.
    Wang X; Zhang F; Zhao C; Wang Z; Nichols WW; Testa R; Li H; Chen H; He W; Wang Q; Wang H
    Antimicrob Agents Chemother; 2014; 58(3):1774-8. PubMed ID: 24342639
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
    Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
    J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of
    Mataraci Kara E; Yilmaz M; İstanbullu Tosun A; Özbek Çelik B
    Infect Dis (Lond); 2020 Sep; 52(9):616-624. PubMed ID: 32427010
    [No Abstract]   [Full Text] [Related]  

  • 57. A carbapenem-resistant Acinetobacter baumannii outbreak associated with a polymyxin shortage during the COVID pandemic: an in vitro and biofilm analysis of synergy between meropenem, gentamicin and sulbactam.
    Chaiben V; Yamada CH; Telles JP; de Andrade AP; Arend LNVS; Ribeiro VST; Dantas LR; Suss PH; Tuon FF
    J Antimicrob Chemother; 2022 May; 77(6):1676-1684. PubMed ID: 35368079
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
    Boattini M; Comini S; Bianco G; Iannaccone M; Casale R; Cavallo R; Costa C
    J Chemother; 2023 May; 35(3):198-204. PubMed ID: 35731718
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Evaluation of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem, and Colistin Single and Binary Combinations Against Carbapenem Resistant Klebsiella pneumoniae Strains Isolated from Various Clinical Specimens].
    Köle M; Sesli Çetin E; Şirin MC; Cicioğlu Arıdoğan B
    Mikrobiyol Bul; 2022 Apr; 56(2):230-250. PubMed ID: 35477227
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii.
    Wang Y; Li X; Wang D; Sun S; Lu C
    Lett Appl Microbiol; 2020 Mar; 70(3):189-195. PubMed ID: 31808159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.